LPCN 8-K: SEC filing
Lipocine
Filed with the SEC on · accession 0001493152-26-050098
LPCN filed a 8-K (current report) with the SEC on Nov 5, 2026. Lipocine reported Q3 2026 financial results with revenue of $2.3 million versus $115,000 a year earlier, and a narrowed net loss of $0.7 million.
Summary of the filing
Lipocine reported Q3 2026 financial results with revenue of $2.3 million versus $115,000 a year earlier, and a narrowed net loss of $0.7 million. The company also provided pipeline updates, including initiation of the Phase 3 BLOOM study for LPCN 1154 in postpartum depression and Canadian approval of TLANDO.
Key details
✦ Ask GOAX AI about this filing — what it means for LPCN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for LPCN?
Click hereFrequently asked questions
What did LPCN file with the SEC on Nov 5, 2026?
LPCN filed a 8-K (SEC filing). Lipocine reported Q3 2026 financial results with revenue of $2.3 million versus $115,000 a year earlier, and a narrowed net loss of $0.7 million. The company also provided pipeline updates, including initiation of the Phase 3 BLOOM study for LPCN 1154 in postpartum depression and Canadian approval of TLANDO.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other LPCN SEC filings
Get alerts when LPCN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days